Orforglipron Capsules Canada — Capsules
Oral Non-Peptide GLP-1 Receptor Agonist
Orforglipron is an orally available, non-peptide small molecule characterised as an agonist at the glucagon-like peptide-1 (GLP-1) receptor. It is supplied here in capsule form for laboratory research within controlled experimental environments.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
Orforglipron is an orally available, non-peptide small molecule characterised as an agonist at the glucagon-like peptide-1 (GLP-1) receptor. It is supplied here in capsule form for laboratory research within controlled experimental environments.
In published work, orforglipron has been examined primarily in human pharmacology studies describing its oral disposition and bioavailability, in comparative studies of capsule and tablet presentations, and in the design of clinical trials evaluating GLP-1 receptor agonism in populations with obesity or overweight.
Third-party tested for purity, ID, quantity.
Coming Soon
The certificate of analysis for this lot is being finalised and will be published here as soon as the lab returns it.
Orforglipron is described in the literature as a small-molecule, non-peptide agonist of the GLP-1 receptor, a class distinguished from peptide analogues by oral absorption without the formulation constraints associated with peptide delivery. The published record addresses how the molecule behaves after oral administration rather than detailed receptor-level characterisation, so mechanistic description beyond GLP-1 receptor agonism is not well documented in the references available here.
Research endpoints reported to date centre on clinical pharmacology: absolute oral bioavailability and disposition in healthy participants, and pharmacokinetic comparison between capsule and tablet formulations in participants with obesity or overweight. A separate phase 3 trial programme has been described in design and baseline-characteristics form, examining orforglipron in adults with moderate-to-severe obstructive sleep apnoea and obesity or overweight; that publication reports study structure and enrolled population rather than outcomes.
Orforglipron emerged from efforts to develop orally administered non-peptide agonists at the GLP-1 receptor, a target previously addressed mainly through injectable peptide analogues. The detailed discovery and medicinal chemistry history of the compound is not documented in the references available here.
The accessible published record is recent and concentrated in clinical pharmacology and trial-design reporting. Studies have characterised oral disposition and absolute bioavailability in healthy participants, established pharmacokinetic bioequivalence between capsule and tablet presentations, and set out the design of a phase 3 programme in obstructive sleep apnoea. Outside these areas the literature base remains limited.
Orforglipron appears in research frameworks concerned with oral GLP-1 receptor agonism by non-peptide molecules. Published investigations have addressed clinical pharmacokinetics, including absolute bioavailability and disposition following oral administration, and formulation comparability between capsule and tablet presentations. It also features in the published design and baseline characterisation of a phase 3 trial in adults with obstructive sleep apnoea and obesity or overweight. The overall published record is small and oriented toward pharmacology and trial methodology rather than mechanistic or preclinical work.
4 of the 5 areas below are addressed directly by a paper cited on this page.
No paper cited on this page reports on receptor, agonist or pharmacology. This heading marks where Orforglipron Capsules is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Addressed on this page by Morse 2026. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Ma 2026. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Malhotra 2026, Ma 2026. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Malhotra 2026. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
The references section of this page cites 3 primary papers published in 2026 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Orforglipron Capsules is frequently listed as a peptide by suppliers in this market. It is not one. The structure published on this page is the compound's actual chemistry, and research on it should be read against its own class rather than against peptide literature.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Orforglipron Capsules, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Orforglipron Capsules is commonly described online in connection with weight loss, appetite suppression and fat reduction. In the research literature the same compound is filed under GLP-1 receptor agonist pharmacology, oral small-molecule bioavailability studies and formulation pharmacokinetic comparability.
Of the 3 papers cited on this page, published between 2026 and 2026, 3 report work in human participants — Morse 2026, Ma 2026 and Malhotra 2026. Human data for a molecule is not the same as evidence for material supplied as a research compound: published trials use pharmaceutical-grade product under medical supervision at defined doses. What is established for the material sold here is its measured purity and content per lot.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Every lot of Orforglipron Capsules is independently assayed before it is released, and the certificate for the lot shipped is published rather than summarised. Where a certificate for a current lot is not yet posted, the lot has not yet been released against it.
Researchers who buy Orforglipron Capsules in Canada through Eppix Labs receive a batch-labelled vial whose certificate is published against that lot code, so the material can be matched to its analysis rather than to a generic specification.
Orforglipron Capsules is supplied in capsule form, which removes the reconstitution step entirely: there is no vehicle to add, no reconstitution volume to record and no post-reconstitution stability window to track. What that leaves a laboratory to control is storage — capsule shells draw moisture from the air, so the container should be kept sealed and dry rather than decanted into an open vessel.
Because the material is already at its labelled quantity per capsule, batch verification carries more weight in this format than it does for powder: there is no point at which the researcher independently confirms mass by weighing. The measured content published for each lot is the figure that answers that question.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each capsule contains the labeled quantity of orforglipron. Independent third-party analysis verifies purity, identity, and net content per batch.
The container holds only the capsules. Any laboratory materials required for handling, extraction, or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants
PubMedPharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight
PubMedOrforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trial
PubMedRelated
Eppix Flash Sale −30%Capsules
PDE5 Inhibitor Research Compound Tadalafil is a small-molecule phosphodiesterase type 5 (PDE5) inhibitor supplied in capsule form for laboratory research. It is handled as a reference compound in controlled experimental and analytical settings.
$38.46$54.95CAD
Flash sale ends in
Eppix Flash Sale −30%Capsules
AMPA Receptor Potentiator TAK-653 is a small molecule described in the literature as an AMPA receptor positive allosteric modulator. It is supplied in capsule form strictly for laboratory research use.
$66.47$94.95CAD
Flash sale ends in
Eppix Flash Sale −30%Capsules
Unidentified Capsule Preparation SANA Capsules is supplied as a capsule-format research item. No molecular identity, sequence, or defined active constituent could be established for this designation from the available chemical records or published literature.
$66.47$94.95CAD
Flash sale ends in
Eppix Flash Sale −30%Capsules
Synthetic Dipeptide Compound Noopept is a synthetic dipeptide compound supplied in capsule form for laboratory research. It is handled exclusively within controlled experimental environments.
20.34 mg
$17.46$24.95CAD
Flash sale ends in
